Floatz logo

Vorolanib

Thymic Carcinoma

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Thymic Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 2B
Fludarabine
Beijing Biotech
Phase 2B
Busulphan
Roswell Park Cancer Institute
Phase 2B
CYCLOSPORIN A
Roswell Park Cancer Institute
Phase 2B
Evomela
Roswell Park Cancer Institute
Phase 2B

View all 26 →

Same molecule, other indications

Vorolanib is also rated in:

renal cell carcinomaDormant
B
Indicative ·
61 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →